Data Exclusivity

[Part III] The Trial of Data Exclusivity

In the third part of the post on data exclusivity (see here for Part I and Part II), Arnav explores whether there are alternative ways to incentivise domestic pharmaceutical innovation and clinical trials without introducing a data exclusivity regime. In this post, he examines possible policy interventions and alternative models, including a compensatory liability framework, while also highlighting the need for meaningful public consultation before any such policy decisions are made. Arnav is a 5th-year law student from Rajiv Gandhi

[Part III] The Trial of Data Exclusivity Read More »

[Part I] The Trial of Data Exclusivity

With reports suggesting that the Organization of Pharmaceutical Products in India is pushing for up to 10–12 years of data exclusivity protection in India, the debate over affordable medicines and pharmaceutical innovation is once again gaining momentum. But what would such a regime mean for India’s carefully negotiated patent bargain, generic competition and access to medicines? In Part I of the three-part post, Arnav Kaman examines the parallels between patent protection and data exclusivity, and the important questions that the

[Part I] The Trial of Data Exclusivity Read More »

India’s Intellectual Property Policy Needs Evidence, Not Faith

Views expressed in this piece and in the TIF piece are author’s own. Vanakam readers! I have written a longish piece for the India Forum (TIF) on why we need more evidence to justify the current subject matter expansion that is taking place across various domains (from GUIs to GenAI to data exclusivities) and not simply operate on faith. This lament is not new; previously, Prof. Basheer and Swaraj, in many different words, brought up the same concern. The context

India’s Intellectual Property Policy Needs Evidence, Not Faith Read More »

Announcing the 2026 Shamnad Basheer Essay Competition on Intellectual Property Law

Celebrating the 50th birth anniversary of Prof. Basheer, earlier this year, we had promised to return with the 2026 edition of the Shamnad Basheer Essay Competition on Intellectual Property Law. And we are now delighted to announce the launch of this year’s competition! A master with the pen, Prof. Basheer continues to inspire us with his ability to make complex legal ideas accessible to a wider audience. Our long-time readers, and the many others who have engaged with his work,

Announcing the 2026 Shamnad Basheer Essay Competition on Intellectual Property Law Read More »

Tariff-Secrecy Double Bind: How Global Trade Rules Undermine Pharmaceutical Access In The Global South

Examining the growing structural gap between TRIPS’ public-health objectives and the contemporary political economy of pharmaceuticals, Tanya Verma in her entry for the SpicyIP-jhana Blogpost Writing Competition, argues that tariff regimes and expanding trade-secret protections together create a “double bind” that constrains the Global South’s ability to both import and manufacture medicines. Tanya is a fifth year student at Dr. Ram Manohar Lohiya National Law University, Lucknow. Tariff-Secrecy Double Bind: How Global Trade Rules Undermine Pharmaceutical Access In The Global

Tariff-Secrecy Double Bind: How Global Trade Rules Undermine Pharmaceutical Access In The Global South Read More »

A Look Back at India’s Top IP Developments of 2025

[This post is completely human authored 🙂 These humans include – Praharsh Gour, Vasundra Koul, Arshiya Gupta, and Vikram Raj Nanda. Selection and Supervision by- Praharsh Gour, Swaraj Paul Barooah, and Bharathwaj RamakrishnanResearch Inputs from Yohann Titus Mathew, Riddhi Yogesh Bhutada, Ayush Shetty, Sumit Kumar Singh, Shailraj Jhalnia, Himanshu Mishra, Bhavya Gupta, Aali Jaiswal, Anushka Kanabar, Srishti Gaur, Arshya Wadhwa, and Daanish Naithani.] 2025 was quite an eventful year. On the judicial side, we saw a variety of novel developments, such

A Look Back at India’s Top IP Developments of 2025 Read More »

Data Exclusivity Debate Resurfaces Amidst US-FTA Talks, Evidence Still Missing

(Long post ahead!) A Central Drugs Standard Control Organization (CDSCO) notice has triggered fresh discussions on a data exclusivity regime for pharmaceutical products in India. The notice dated October 8 invites comments ‘to ensure a level playing field in new drug approval’. The notice reasons that  applicants obtaining approval of a new drug for the first time in the country based on clinical trial and test data do it at a higher regulatory compliance cost compared to subsequent applicants who

Data Exclusivity Debate Resurfaces Amidst US-FTA Talks, Evidence Still Missing Read More »

Image with SpicyIP logo and the words "Weekly Review"

SpicyIP Weekly Review (December 1 – December 7)

Starting the month with an analysis of the Delhi HC’s judgment in Novo v. Reddy in the Ozempic dispute. Section 3(k) in the news again in Ab Initio v. Controller, and a trademark battle over the word ‘choice’. This and much more in this week’s SpicyIP Weekly Review. Anything we are missing out on? Drop a comment below to let us know.  Highlights of the Week Part I- Novo v. Dr. Reddy: Clear the Way or Else Block The Way

SpicyIP Weekly Review (December 1 – December 7) Read More »

Of Clinical Trial Waivers in India: The Misses Outweigh the Hits

In light of the executive order waiving the requirement to conduct clinical trials for new drugs approved in a few selected jurisdictions, we are pleased to bring to you this guest post by Md. Sabeeh Ahmad, discussing the implications of this executive order. Sabeeh is an Advocate and is a law graduate from AMU, Aligarh. His previous posts can be accessed here. Of Clinical Trial Waivers in India: The Misses Outweigh the Hits By Md. Sabeeh Ahmad The Drug Controller General

Of Clinical Trial Waivers in India: The Misses Outweigh the Hits Read More »

Orange Book & Inaccurate Patents: US Federal Trade Commission in Action

[This post is co-authored by SpicyIP Intern Pranav Aggarwal and Swaraj Paul Barooah. Pranav is a second-year student pursuing B.A.LL.B.(Hons) at Rajiv Gandhi National University of Law, Punjab. He has a keen interest in commercial laws, especially in IP and allied fields. His previous posts can be accessed here.] On 7th November 2023, the Federal Trade Commission (“FTC”) issued a press release announcing its challenge to more than 100 patents listed in the ‘Orange Book’. These patents which belong to ten

Orange Book & Inaccurate Patents: US Federal Trade Commission in Action Read More »

Scroll to Top